Comparison of gene mutational status between primary colorectal carcinoma and paired synchronous/metachronous liver metastasis by next-generation

Abstract

Abstract: Purpose: To compare the gene mutational status between primary colorectal carcinoma (CRC) and paired synchronous/metachronous liver metastasis. Methods: KRAS, NRAS, BRAF and PIK3CA mutations were analyzed in 29 patients with primary and paired synchronous liver metastatic CRC, and in 26 patients with primary and paired metachronous liver metastatic CRC using next-generation sequencing (NGS). Results: Same mutation profiles of KRAS, NRAS, BRAF or PIK3CA between primary and paired synchronous liver metastatic CRCs were observed in 27 of 29 patients (93.1%). Of 2 patients with discordant mutational status, a KRAS mutation was detected in the primary tumor and one of liver metastatic tumors in a patient, but no mutation was observed in the other liver metastatic lesion. A PIK3CA mutation was observed in primary tumor but not the metastatic tumor in the other patient. Moreover, same mutation profiles between primary and paired metachronous liver metastatic CRCs were observed in 21 of 26 patients (80.8%), which was significantly lower than those in paired primary and synchronous liver metastatic CRCs (P =0.010). Of 5 patients with discordant mutational status, KRAS, NRAS, or PIK3CA mutations were observed in the metastatic tumors but not the primary tumors in 4 patients, whereas a KRAS mutation was detected in the primary tumor but not the metastatic tumor in 1 patient. Conclusions: The gene mutational discrepancies are more frequently observed in paired primary/metachronous liver metastatic CRCs than paired primary/synchronous liver metastatic CRCs.

Key words: Colorectal carcinoma, Synchronous liver metastasis, Metachronous liver metastasis, Next-generation sequencing, Gene mutation

Li Weihua, Li Yan, Guo Lei, Ying Jianming. Comparison of gene mutational status between primary colorectal carcinoma and paired synchronous/metachronous liver metastasis by next-generation[J]. Electronic Journal of Liver Tumor, 2020, 7(1): 39-44.

References

[1] Siegel RL, Miller KD, Fedewa SA, et al.Colorectal cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(3): 177-193.
[2] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66(2): 115-132.
[3] Paschos KA, Majeed AW, Bird NC.Natural history of hepatic metastases from colorectal cancer--pathobiological pathways with clinical significance[J]. World J Gastroenterol, 2014, 20(14): 3719-3737.
[4] Comprehensive molecular characterization of human colon and rectal cancer[J]. Nature, 2012, 487(7407): 330-337.
[5] Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al.Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies[J]. Cancer Res, 2007, 67(6): 2643-2648.
[6] Nakayama I, Shinozaki E, Matsushima T, et al.Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients[J]. BMC Cancer, 2017, 17(1): 38.
[7] Li W, Qiu T, Guo L, et al.Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing[J]. Cancer Lett, 2017, 410: 92-99.
[8] Han CB, Li F, Ma JT, et al.Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review[J]. Cancer Invest, 2012, 30(10): 741-747.
[9] Goswami RS, Patel KP, Singh RR, et al.Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors[J]. Clin Cancer Res, 2015, 21(11): 2644-2651.
[10] Haley L, Tseng LH, Zheng G, et al.Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers[J]. Mod Pathol, 2015, 28(10): 1390-1399.
[11] Mekenkamp LJ, Koopman M, Teerenstra S, et al.Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases[J]. Br J Cancer, 2010, 103(2): 159-164.
[12] Hsu HC, Thiam TK, Lu YJ, et al.Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients[J]. Oncotarget, 2016, 7(16): 22257-22270.
[13] Mao C, Yang ZY, Hu XF, et al.PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis[J]. Ann Oncol, 2012, 23(6): 1518-1525.
[14] Lee SY, Haq F, Kim D, et al.Comparative genomic analysis of primary and synchronous metastatic colorectal cancers[J]. PLoS One, 2014, 9(3): e90459.
[15] Vignot S, Lefebvre C, Frampton GM, et al.Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles[J]. Eur J Cancer, 2015, 51(7): 791-799.
[16] Mao C, Wu XY, Yang ZY, et al.Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases[J]. Sci Rep, 2015, 5: 8065.
[17] Punt CJ, Koopman M, Vermeulen L, From tumour heterogeneity to advances in precision treatment of colorectal cancer[J]. Nat Rev Clin Oncol, 2017, 14(4): 235-246.
[18] Findlay JM, Castro-Giner F, Makino S, et al.Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy[J]. Nat Commun, 2016, 7: 11111.
[19] Jiang YZ, Yu KD, Bao J, et al.Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer[J]. Cancer Res, 2014, 74(13): 3399-3407.
[20] Bai H, Wang Z, Chen K, et al.Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer[J]. J Clin Oncol, 2012, 30(25): 3077-3083.